New data show Farxiga significantly lowers the risk of cardiovascular death in patients with heart failure
Pre-specified pooled analysis from Phase III trials demonstrated reduction in CV death by 14% and reduction in death from any cause by 10% in patients with heart failure irrespective of ejection fraction.First heart failure medication to demonstrate mortality benefit across the full ejection fraction range.Results being presented at the European Society of Cardiology annual meeting and simultaneously published in Nature Medicine.Today, new results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga (